Stockwinners Market Radar for February 02, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:16 EST Nordstrom ends afterhours session up 31% after WSJ report on Ryan Cohen stake

19:08 EST Avista raises quarterly dividend 4.5% to 46c per share - Avista Corp.'s board of directors has declared a quarterly dividend of 46c per share on the company's common stock, an increase of 2c per share or 4.5%, yielding an annualized dividend of $1.84. The common stock dividend is payable March 15, 2023, to shareholders of record at the close of business on Feb. 17, 2023. "The dividend increase approved by the board of directors marks the twenty-first consecutive year the board has raised the dividend for our shareholders. I believe it demonstrates the board's commitment to maximizing shareholder value," said Avista President and Chief Executive Officer Dennis Vermillion.

18:25 EST Netflix, GM partner to increase EV presence in Netflix-produced shows, films - General Motors (GM) and Netflix (NFLX) are partnering to increase the presence of electric vehicles in Netflix-produced shows and films, where relevant, while also taking steps to enable more sustainable productions. "Entertainment has a huge impact on culture. We want to make EVs famous on streaming, small and silver screens to build an EV culture through storytelling that incorporates the experiences of driving and owning an EV," said GM Global Chief Marketing Officer Deborah Wahl. "Netflix is a great partner because of the company's compelling storytelling, commitment to sustainability and track record of sparking conversations that shape cultural trends. We are united in creating a better, more sustainable future for our world as we bring everybody in on EVs." As a result of the partnership, Netflix is supporting and educating creators, helping them to better understand how EVs can complement and enhance their stories. Over the course of the next year, inspired by this partnership, GM EVs will be seen in select Netflix shows and films, including Love is Blind, Queer Eye and Unstable, which will feature the Chevrolet Bolt EUV, GMC HUMMER EV Pickup and Cadillac LYRIQ respectively. Reference Link

18:09 EST Starbucks says no labor shortage issues - Says seeing strong applicant flow.

18:02 EST Apple pares decline during Q1 conference call, now down 1% at $149.35 afterhours

17:59 EST Amazon says YTD AWS revenue growth in mid-teens y/y so far - Says optimization efforts expected to continue to be a headwind to AWS growth in at least the next couple of quarters. Says new AWS customer pipeline remains healthy and robust.

17:55 EST Apple CFO says y/y performance of Q2 to be similar to Q1 - CFO Luca Maestri says: "Given the continued uncertainty around the world in the near term, we are not providing revenue guidance, but we are sharing some directional insights based on the assumption that the macroeconomic outlook and COVID-related impacts to our business do not worsen from what we are projecting today for the current quarter. In total, we expect our March quarter year-over-year revenue performance to be similar to the December quarter. This represents an acceleration in our underlying year-over-year business performance as the December quarter benefited from an extra week. Foreign exchange will continue to be a headwind, and we expect a negative year-over-year impact of 5 percentage points. For Services, we expect revenue to grow year-over-year while continuing to face macroeconomic headwinds in areas such as digital advertising and mobile gaming. For iPhone, we expect our March quarter year-over-year revenue performance to accelerate relative to the December quarter year-over-year revenue performance. For Mac and iPad, we expect revenue for both product categories to decline double digits year-over-year because of challenging compares and macroeconomic headwinds. We expect gross margin to be between 43.5% and 44.5%. We expect OpEx to be between $13.7 billion and $13.9 billion." Comments taken from Q1 earnings conference call.

17:49 EST Amazon saw continued efficiencies in transportation network in Q4 - Says NFL Thursday Night Football reached youngest median audience for any national football broadcasts. Comments taken from Q4 earnings conference call.

17:31 EST Getaround announces restructuring plan, 10% workforce reduction - Getaround announced the company will streamline operations and reduce costs to achieve a leaner path to profitability. These changes also include a workforce reduction, effective immediately, that impacts approximately 10% of the company's current staff. The restructuring plan also includes significant reductions to other operating expenses, including reducing the company's contract workforce, and outside professional services. This revised global business strategy is intended to fortify the company's path to achieve sustainable profitability and long-term growth. Together, these reductions to the company's operating expenses are estimated to result in cost savings of between $25M-$30M on an annualized run-rate basis. "In response to an uncertain near-term macroeconomic outlook, which has hit technology companies particularly hard, Getaround has made the decision to streamline its operations," said Sam Zaid, Getaround CEO. "These proactive changes include a difficult, but necessary, reduction in our North American workforce. Through these changes, we will maintain and prioritize Getaround's spirit of innovation and long-term focus on profitably growing our global marketplace at a measured and efficient pace, while, at the same time, optimize the Company's underlying cost structure. Getaround continues to benefit from strong demand in the U.S. and Europe, as we continue to lead the digital carsharing transformation." Zaid continued, "While this was a necessary step to maintain financial health and the long-term success of Getaround, with much sadness, I want to say thank you to our departing colleagues for your contributions, the energy you have brought to the team, and the impact you have had building Getaround into a global marketplace."

17:30 EST Ford sees FY23 capital expenditures $8B-$9B - Says expects big strong year for share growth. Says Ford Blue is a growth business for the foreseeable future. Says has been number one in recalls over last two years which is unacceptable. Says EV sales growth is twice the rate of the EV segment. Says remains on track to realize annual EV production of 50,000 per month. Says software and experiences will be key differentiator for the industry. Says 2022 results fell short of expectations. Says has more work to do in China. Says 2023 is a pivotal year. Comments and guidance taken from Q4 earnings conference call.

17:22 EST Apple CFO Maestri says customer satisfaction for iPhone 14 at 98% - Says customer satisfaction with Mac at 96%, according to survey data from 451 Research. Comments taken from Q1 earnings conference call.

17:18 EST Northrop Grumman enters $500M ASR agreement - Northrop Grumman announced that it has entered into an accelerated share repurchase, or ASR, agreement with Bank of America to repurchase $500M of Northrop Grumman's common stock. The ASR is in addition to previously planned repurchases, including open market share repurchases. The company continues to target returning more than 100% of its free cash flow to shareholders through dividends and share repurchases in 2023. Under the ASR agreement, Northrop Grumman expects to receive an initial delivery of approximately 0.9M shares on February 6, representing approximately 80% of the expected share repurchases under the ASR agreement, based on the company's closing price of $440.86 on February 2. The final number of shares to be repurchased through the ASR will be based on Northrop Grumman's volume-weighted average price during the term of the transaction, less a discount, and is expected to be completed no later than the second quarter of 2023. The ASR will be completed under the company's current share repurchase authorization, which currently has approximately $2.5B remaining.

17:11 EST DavidsTea announces temporary lay-off of 15% of head-office staff - DAVIDsTEA announced a plan to adjust its cost structure amid continuing macro-economic uncertainty. "Like many other retail brands, we experienced difficult market conditions in the Q4 as consumer wallets were impacted by rising inflation and higher interest rates that reduced demand," explained Sarah Segal, CEO. "The decision to implement a cost-containment plan is necessary to align our cost structure with our current sales level to sustain our digital-first, omnichannel growth strategy. We are also in the process of addressing certain operational issues that affected the overall consumer experience earlier in the quarter. Despite these challenges, we firmly believe in our long-term growth plan and vision. Our goal remains focused on delivering high-quality, loose-leaf teas, accessories and gifts alongside a superior consumer experience, in the most efficient and leading way possible." The Company has implemented several cost cutting measures on its path to profitability, including the temporary lay-off of 15% of head-office staff and cutting other expenses by $6.0M-$8.0M. These reductions consist of the elimination of IT transformation investments of $4.0M undertaken in FY22 that will be in maintenance mode in FY23. SG&A costs on a pro-forma basis are expected to be reduced between $8.0M-$10.0M in FY23. The Company continues to manage its cash and working capital with a cash position of approximately $22.0M at year end, no debt and a solid working capital position. More details about the cost-containment plan will be outlined when DAVIDsTEA releases its fourth quarter results for FY22 on April 28.

17:09 EST Alphabet says started bringing revenue sharing to YouTube Shorts - Says revenues were impacted by pull backs in advertiser spend and foreign exchange. Says AI is most profound technology the company is working on today. Says language models is an area of opportunity. Says this week started bringing revenue sharing to YouTube Shorts. Says YouTube shorts has surpassed 50B daily views. Says YouTube music and YouTube premium surpassed 80M subscribers. Says Sunday ticket will help drive subscriptions, bring new users and create opportunities for creators. Says despite ongoing revenue headwinds in Q4, confident in YouTubes direction. Says meaningfully slowing the pace of hiring in 2023. Says most of workforce reduction impact will be seen in Q1 with $1.9B-$2.3B in severance costs Sees FY23 capital expenditures in line with FY22. Comments and guidance taken from Q4 earnings conference call.

17:08 EST Apple CEO Cook says production has returned to 'where we want it to be' - Says company set all-time revenue records in a number of markets, including Canada, Indonesia, Mexico, Spain, Turkey and Vietnam, along with quarterly records in Brazil and India. Says faced foreign exchange, macro, and COVID related challenges in the quarter. Says "because of these constraints, we had significantly less iPhone 14 Pro and iPhone 14 Pro Max supply than we planned, causing ship times to extend far beyond what we had anticipated." Says iPhone revenue on constant currency basis was 'roughly flat'. Says Mac revenue was in line of what was expected, faced difficult compares for Mac. Comments taken from Q1 earnings conference call.

16:55 EST SBC Medical to become public through Pono Capital Two merger - Pono Capital Two has announced the execution of a definitive agreement and plan of merger with SBC Medical Group Holdings Incorporated, a Delaware corporation. Pursuant to the merger agreement, it is intended that SBC will merge with Pono Two Merger Sub, Inc., a wholly owned subsidiary of Pono, with SBC continuing as the surviving corporation as a wholly owned subsidiary of Pono. Stockholders of SBC will receive shares of Class A Common Stock of Pono. In connection with the merger, it is expected that SBC will change its name to SBC Medical Operations and that Pono will then change its name to SBC Medical Group Holdings Incorporated. As a condition to the closing of the merger, SBC will complete a restructuring of certain of its affiliates, such that they will become subsidiaries of SBC. The discussion of the business of SBC as described below assumes that this restructuring has been completed, as these subsidiaries are currently the entities undertaking such business operations. Pono and SBC believe that, if consummated, the merger will promote the expansion of the SBC's business globally, as SBC will be better positioned to become the global standard for medical services, marketing and cosmetic procedures. The transaction values SBC at $1.2B, which is expected to result in a combined pro forma equity value of approximately $1.36B, assuming no redemptions in the merger. The cash proceeds raised in the transaction, after any redemptions and payment of transaction expenses, are currently anticipated to be used for opening new clinics, developing new product lines and for general company operating purposes. The boards of directors of SBC and Pono have unanimously approved the merger agreement and the proposed transactions. The closing of the merger and related transactions are subject to approval by Pono stockholders and SBC's stockholders, and are also subject to other customary closing conditions. It is currently expected that the transaction will close in the fourth quarter of 2023 or the first quarter of 2024, assuming such closing conditions are met.

16:51 EST Liquidia announces PTAB backs decision to invalidate United Therapeutics claims - Liquidia (LQDA) announced that the PTAB has reaffirmed its original decision in the '793 IPR, which found all claims of the '793 patent to be unpatentable due to the existence of known prior art cited by Liquidia. In denying United Therapeutics' (UTHR) request for a rehearing and for a reconsideration of the PTAB's decision in the '793 IPR, the PTAB clarified that the publications cited by Liquidia constituted prior art due to public distribution at large medical conferences more than a year before the filing of the initial patent application that led to the issuance of the '793 patent. Based on earlier statements, UTHR is expected to file an appeal of the PTAB decision to the U.S. Court of Appeals for the Federal Circuit. The deadline for UTHR's appeal is 63 days from the date on which UTHR's rehearing request was denied. If the PTAB's decision on the '793 IPR is affirmed on appeal, then the '793 patent will be cancelled, overriding any finding of infringement in the lawsuit filed by UTHR against Liquidia under the Drug Price Competition and Patent Term Restoration Act in the U.S. District Court for the District of Delaware.

16:42 EST Shift Technologies to exit East Coast stores acquired via CarLotz merger - Shift Technologies has announced it will be exiting its East Coast stores acquired as a result of its merger with CarLotz, Inc. in order to focus on building omnichannel capabilities in its other locations and on the company's path to profitability. The store leases, inventory, and related assets in Richmond, Virginia, Charlottesville, Virginia, and Tampa, Florida, will be assumed by a local dealership group. The stores in Midlothian, Virginia, Charlotte, North Carolina, and Greensboro, North Carolina will be closed, effective immediately. In the past few months, Shift has re-introduced in-person selling capabilities at its core West Coast locations. The remaining legacy CarLotz locations in Pomona, California, which will serve the greater Los Angeles area, and Downers Grove, Illinois, which will serve Chicagoland, are being converted to omnichannel Shift locations. Customers are able to shop and purchase Shift's full inventory online, from anywhere in the country, or visit their local Shift to speak to a representative or take a test drive at the store.

16:40 EST TTM Technologies announces SBR to codify Government Security Committee - TTM Technologies announced that pending confirmation by the Defense Counterintelligence and Security Agency, or DCSA, the TTM board of directors has adopted a special board resolution, or SBR, replacing the special security agreement, or SSA, that the company had entered into with the DCSA in 2010. The replacement of the SSA with the SBR is a result of the significantly reduced foreign ownership of TTM. The effective date of the SBR is February 2. The SBR agreement with DCSA codifies the standing Government Security Committee of TTM's board of directors, consisting of at least 3 Board members that hold a National Security Clearance. In addition, the SBR dictates that TTM will maintain its policies and procedures that have been established pursuant to the provisions of the SSA to mitigate risks to TTM's operations that serve the national security of the United States, including the maintenance of its cybersecurity plan that meets the requirements of NIST 800-171. DCSA will continue to review TTM's compliance with the terms of the SBR annually at each of TTM's sites which operate under a U.S. Department of Defense security clearance. This change acknowledges that TTM no longer has any significant foreign owners of its equity. In addition, all of TTM's board is currently comprised of U.S. citizens and per the terms of the SBR, no foreign citizen is allowed to sit on TTM's board in the future.

16:36 EST Parsons receives $15M award for project in Saudi Arabia - Parsons Corporation announced that the company was selected by the Rua Al-Madinah Holding Company, RAM-H, to provide construction project management consultancy and contract administration services, PMCM, for the Rua Al-Madinah mega mixed-use real estate project in the holy city of Al-Madinah Al-Munawarah, Kingdom of Saudi Arabia, KSA . Under the $15M contract, Parsons will manage the main infrastructure works including the tunnel, road, and utility works. "The Kingdom has several megaprojects that are driving the economic and social transformation of the region while highlighting its hospitality and heritage," said Pierre Santoni, president for Middle East and Africa at Parsons. "Parsons is dedicated to helping our client achieve their vision of reforming Madinah into a modern Islamic and cultural destination for pilgrims and a revitalized urban center for its residents."

16:35 EST Apple reports Q1 Wearables, Home and Accessories revenue $13.48B - Reported $14.70B last year.

16:34 EST Apple reports Q1 iPad revenue $9.4B vs. $7.25B last year

16:33 EST Microchip sees FY23 capital expenditures $525M-$545M

16:33 EST Apple declares quarterly dividend of 23c per share - Apple's board of directors has declared a cash dividend of 23c per share of the company's common stock. The dividend is payable on February 16, to shareholders of record as of the close of business on February 13.

16:32 EST Apple CEO Tim Cook highlights 'challenging environment' - Apple CEO Tim Cook said in today's earnings release, "As we all continue to navigate a challenging environment, we are proud to have our best lineup of products and services ever, and as always, we remain focused on the long term and are leading with our values in everything we do. During the December quarter, we achieved a major milestone and are excited to report that we now have more than 2 billion active devices as part of our growing installed base."

16:31 EST Kohl's names Tom Kingsbury as CEO - Kohl's announced its Board of Directors has unanimously appointed Tom Kingsbury as CEO effective as of February 2, 2023. Mr. Kingsbury has served as Interim Chief Executive Officer since December 2, 2022. Mr. Kingsbury will continue to serve on the Company's Board.

16:29 EST Clorox CEO says 'actions we are taking to rebuild margin are working' - "We delivered better-than-expected results this quarter, with strong execution and the benefit of continued brand relevance as well as our ongoing pricing and cost savings efforts," said CEO Linda Rendle. "The actions we are taking to rebuild margin are working, and we are relentlessly driving additional improvements while investing in our brands, categories and capabilities. Going forward, we are confident that our leading product portfolio in essential categories coupled with our proactive actions will enable us to navigate current macroeconomic challenges and return to more consistent profitable growth over time."

16:28 EST Clorox reports Q2 gross margin up 320 bps to 36.2% from 33% a year ago - Due to the benefits of pricing and cost savings initiatives, partially offset by unfavorable commodity costs and mix, and higher manufacturing and logistics costs.

16:27 EST Qualcomm sees Q2 QCT revenue $7.4B-$8B - Sees Q2 QTL revenue $1.25B-$1.45B.

16:24 EST Ford down 6% after Q4 earnings report - Ford shares are down 89c, or 6%, to $13.45 in after-hours trading.

16:23 EST Polaris raises dividend 2% to 65c - Polaris announced that its Board of Directors approved a 2% increase in the regular quarterly cash dividend, raising the payout to 65c per share. This increase represents the 28th consecutive year of Polaris increasing its dividend effective with the Q1 dividend. The dividend will be payable on March 15 to shareholders of record at the close of business on March 1.

16:21 EST Leeds Equity Partners acquires TalentNeuron from Gartner - Leeds Equity Partners announced that it has acquired TalentNeuron, a leading provider of human capital data and insights subscription solutions to corporations, government organizations and educational institutions, from Gartner. Terms of the transaction were not disclosed. TalentNeuron provides subscription data solutions and research and advisory insights that enable over 700 corporations, government organizations and educational institutions to develop their human capital management strategies and address their significant people, skills and resource challenges utilizing a data-informed approach with deep insights, analytics, and expert advice on a global basis. The acquisition of TalentNeuron further builds upon Leeds Equity's strong sector franchise in research, data and insight businesses and its decades of work across the human capital management sector. TalentNeuron represents Leeds Equity's eighth platform investment in its most recent buyout fund, Leeds Equity Partners VII, a $1.4B investment fund. Latham & Watkins served as legal counsel and Alvarez & Marsal served as operational advisor to Leeds Equity Partners. Evercore served as financial advisor and Gibson Dunn & Crutcher provided legal counsel to Gartner.

16:19 EST Aimco board names Stone chairman - Apartment Investment and Management Company announced that its Board of Directors has named R. Dary Stone as Chairman of the Board, effective February 1, 2023. Mr. Stone was appointed to the Aimco Board in December 2020 and has served in other Board leadership roles at Aimco including Chairman of the Nominating, Environmental, Social, and Governance Committee. He is an accomplished executive who brings investment and finance, real estate, and capital markets experience having served as President of multiple real estate companies, including as President and COO of Cousins Properties. Mr. Stone also brings governance expertise through his current board service at Cousins Properties, where he is Chairman of the Nominating and Governance Committee, and Tolleson Wealth Management and Tolleson Private Bank, as well as prior board positions at Parkway Properties, Baylor University and the Texas Banking Commission. "I'm honored to be able to serve Aimco, its shareholders, and its outstanding Board," said Mr. Stone. "These Board committee changes signal our commitment to driving shareholder value creation while further enhancing the Company's governance profile. The Board and leadership team will continue to engage with shareholders, and be responsive to their feedback, as we execute on the significant opportunities ahead to drive strong returns."

16:18 EST Conmed: Results impacted by implementation of warehouse management system - "We are disappointed that our fourth quarter results were significantly disrupted by the implementation of a new warehouse management system. We are shipping at or above historical daily rates, and we continue to work diligently to increase our efficiency and capacity," commented Curt R. Hartman, CONMED's Chair of the Board, President, and CEO. "I am pleased with our team's accomplishments in 2022, including the acquisitions of In2Bones and Biorez, the closing of our convertible senior notes offering, and the continued work on new product innovation across the company. We enter 2023 focused on execution and delivery of revenue and earnings growth."

16:16 EST Rigel announces publication summarizing results from Phase 2 study of REZLIDHIA - Rigel Pharmaceuticals announced a peer-reviewed publication of data in Blood Advances, which summarizes clinical results from the Phase 2 registrational study of REZLIDHIA, or olutasidenib, a potent, selective, oral, small-molecule inhibitor of mutant isocitrate dehydrogenase 1, or mIDH1, in patients with mIDH1 relapsed or refractory acute myeloid leukemia (R/R AML). The published data demonstrate that REZLIDHIA induced durable remissions and transfusion independence with a well-characterized safety profile. The observed efficacy is clinically meaningful and represents a therapeutic advance in this poor prognosis patient population with limited treatment options. The pivotal cohort of the Phase 2 registrational study enrolled 153 adult patients with mIDH1 R/R AML who received REZLIDHIA monotherapy 150 mg twice daily orally. The efficacy evaluable population included 147 patients with centrally confirmed mIDH1. The primary endpoint was a composite of complete remission, or CR, plus complete remission with partial hematologic recovery, or CRh. REZLIDHIA demonstrated a 35% CR+CRh rate in mIDH1 R/R AML patients. Of the patients who achieved the primary endpoint of CR+CRh, 92% were CR. Most patients who achieved CR or CRh responded early, with a median time to response of 1.9 months. The overall response rate was 48%. Response rates were similar in patients who had and who had not received prior venetoclax.

16:13 EST Bill.com announces $300M share repurchase program - Bill.com announced that its Board of Directors approved a share repurchase program with authorization to purchase up to $300 million of BILL's common stock. "The share repurchase program demonstrates our confidence in the strength of our business and our ability to capture the large market opportunity ahead of us," said John Rettig, BILL CFO. "With our strong balance sheet and cash flow generation, we are well positioned to invest for our future growth prospects while also returning capital to shareholders and minimizing dilution."

16:10 EST Gilead raises quarterly dividend 2.7% to 75c per share - The dividend is payable on March 30, 2023, to stockholders of record at the close of business on March 15, 2023.

16:09 EST Exponent increases quarterly dividend payment from 24c to 26c per share - Exponent announced that its Board of Directors has raised its quarterly dividend from 24c to 26c per share of common stock. The quarterly cash dividend of 26c per share of common stock is to be paid on March 24, 2023 to all common stockholders of record as of March 10. "Exponent is deeply committed to delivering long-term value for our shareholders. In 2022, we returned $205.1 million to shareholders in the form of $49.2 million in dividends and $155.9 million in common stock repurchases, and ended the year with $161.5 million in cash and cash equivalents," commented Dr. Catherine Corrigan, President and Chief Executive Officer. "The increase in our regular cash dividend demonstrates the strength of our balance sheet and our ongoing commitment to creating value for our shareholders."

16:07 EST Exponent sees FY23 EBITDA 28%-28.5% of revenues before reimbursements - Sees FY23 revenues before reimbursements up high-single to low-double digits. "For decades, Exponent has stood firmly at the forefront of engineering and scientific excellence, unraveling complexity and illuminating the path forward for clients. Our exceptional talent and multidisciplinary approach position us as a vital partner in helping address our clients' toughest challenges. We remain optimistic about the strength of Exponent's unique market position, adaptable business model, and strong client relationships. As we look to the year ahead, we remain keenly focused on positioning the company for continued success and creating long-term value for our shareholders," concluded Corrigan.

16:05 EST Alphabet reports Q4 Google Cloud revenue $7.3B vs. $5.54B last year

16:05 EST Amazon down fractionally after Q4 report, Q1 guidance

16:04 EST Amazon reports Q4 AWS net sales $21.38B vs. $17.78B a year ago - Amazon reports Q4 AWS operating income of $5.21B vs. $5.29B a year ago.

16:01 EST Iteris names Kerry Shiba as new CFO - Iteris announced that Kerry A. Shiba will join the company as senior vice president & CFO effective February 3, 2023. Shiba will report to Joe Bergera, Iteris president and CEO, and will oversee the company's finance, information systems, legal, supply chain, and manufacturing functions.

15:04 EST Managed care stocks under pressure on lower preliminary Medicare Advantage rate - Shares of UnitedHealth (UNH), Humana (HUM), and other managed care names are under pressure on Thursday on lower than expected preliminary Medicare Advantage rates for 2024. The expected average change in revenue is indicated to be about 1%. Reference Link

14:50 EST Disney sends letter to shareholders, does not endorse Trian's Peltz for board - The Walt Disney Company board of directors responded to materials issued by the Trian Group, stating in a letter to shareholders: "The Disney Board of Directors is focused on delivering long-term sustainable value and continually works to ensure it is comprised of the right mix of experience, skills and perspectives to guide Disney, particularly as it navigates this dynamic period. The Disney Board of Directors does not endorse Nelson Peltz (or his son Matthew, who is running as an alternate Mr. Peltz may swap in) as a nominee, and believes the election of either Mr. Peltz or his son would threaten the strategic management of Disney during a period of important change in the media landscape... The Company expects to mail its proxy materials, including its WHITE proxy card, to all shareholders in the near future. The Disney Board urges shareholders to take no action at the moment and to simply discard any materials or blue proxy card they may receive from Trian Group. Shareholders should instead give themselves the benefit of voting on a fully informed basis, taking the Board and management team's important update on its strategy to create value into consideration." Reference Link

13:20 EST Cyngn granted patent for virtual bumper technology - Cyngn said via Twitter that, "Big news! We have just been granted a patent for our virtual bumper technology. This patent enables AI-powered detection of objects and further strengthens our commitment to continually improving the effectiveness, accuracy, and safety of our industrial AVs."Reference Link

13:04 EST Partner Communications announces dismissal of motion for class action - Partner Communications Company announced, that, further to the Company's immediate report on November 8, 2020, regarding the receipt of two lawsuits and a motion for the recognition of these lawsuits as class actions, filed against Partner and its subsidiaries in the Tel Aviv-Jaffa District Court, according to which the Respondents charged the customers a fee for an internet access service provider service after they began receiving this service from another company and that the Respondents did not provide the Service, in an over collected amount estimated in the Motion at over NIS 100M, on February 1, 2023, a verdict was given according to which the Motion is dismissed, while charging the applicants with costs.

12:44 EST Sony rolls out PS5 software beta Discord Voice Chat, VRR support for 1440p - Sony's PlayStation unit said it is rolling out the next PS5 system software beta with a number of fan-requested features, including Discord voice chat and Variable Refresh Rate support for 1440p resolution. The company is also introducing a variety of UX, accessibility and social feature enhancements that make playing with friends or enjoying gaming experiences on the PS5 console "easier than ever." Invited beta participants from the U.S., Canada, Japan, U.K., Germany, and France will receive an email with instructions on how to download the beta and get started. As with previous betas, some features may not make it into the final version or may see significant changes when the final system update releases globally in the coming months.

12:26 EST Microsoft launches Teams Premium with OpenAI features - Microsoft said in a blog post yesterday that Microsoft Teams Premium is generally available Built on the familiar, all-in-one collaborative experience of Microsoft Teams, Teams Premium brings the latest technologies, including Large Language Models powered by OpenAI's GPT-3.5, to make meetings more intelligent, personalized, and protected-whether it's one-on-one, large meetings, virtual appointments, or webinars, the company said. "With more than 400 new features and improvements added to Microsoft Teams last year, and many more to come in 2023, all Teams users can count on continued innovation to deepen connections and foster collaboration," the company said. "But some customers are looking for Teams to do more-offer more advanced meeting capabilities to increase productivity and help to consolidate their software investments to reduce costs. Today, many organizations not only pay for meeting solutions, but also purchase expensive add-on products for webinars, virtual appointments, meeting intelligence, and more. With Teams Premium, customers can get these advanced meeting capabilities and more for one low cost of USD10 per user per month. And, for a limited time, you can get Teams Premium for just USD7 per user per month or 30 percent off the standard price." Reference Link

12:00 EST Canada Goose falls -20.7% - Canada Goose is down -20.7%, or -$5.11 to $19.54.

12:00 EST Enova International rises 19.0% - Enova International is up 19.0%, or $8.69 to $54.49.

12:00 EST Silvergate Capital rises 29.4% - Silvergate Capital is up 29.4%, or $4.77 to $21.01.

11:27 EST TeraWulf CEO says 'priority continues to be reducing costs' - TeraWulf announced that the company's CEO Paul Prager, has issued an open letter to shareholders. The letter read in part, " It has been four weeks since I shared my reflections on TeraWulf's achievements in 2022 and stated goals for 2023. And in that short period, our team has accomplished key milestones that we believe will be foundational in achieving our goal of being the preeminent miner producing bitcoin from zero-carbon energy resources at the lowest marginal cost in the sector. We believe these strategic steps will position TeraWulf for long-term, sustainable growth. Our priority continues to be reducing costs and deploying those resources towards the Company's path to positive cash flow from operations in 2023. In doing so, we believe that we will be able to generate increasing cash flow throughout the year, which will give us further financial leverage to scale our mining operations...After several weeks of constructive dialogue with our lenders, we have reached an agreement on modifying the terms of our debt to eliminate near-term amortization and thereby optimize TeraWulf's financial flexibility through market cycles. Let me be clear - we have a deal that should enable the Company to pay down principal when we have available free cash flow, instead of adhering to a mandatory payment schedule. This is HUGE...In the matter of just a few weeks, we raised what we plan to be the final funding needed to bridge the Company to self-sustaining operations, only a few months away. We have said all along the amount of monies required to achieve free cash flow positive operations, and we have now reached that important milestone...As part of our recent and likely final capital raise, my co-founder and COO, Nazar Khan, and I purchased an additional $2.5 million of equity at the market price. That's right, we bought at market while this transformational equity raise came at a modest discount to the market. Why? Because our confidence in TeraWulf is stronger than ever as we build upon, and begin to realize, our distinguishing advantages.I also want to address the confusion out there regarding the perceived sale of stock. For the avoidance of doubt, I did not sell 12 million shares. I exchanged shares for warrants to free up available authorized common stock ahead of our shareholder meeting later this month to increase the Company's authorized common shares. These warrants will convert back to common stock without any price differential...Every move from this point forward is about advancing our mission and pushing the boundaries of what is possible - for our business and our shareholders. We will remain laser-focused on scaling mining operations at our existing sites while opportunistically pursuing strategic opportunities in a financially responsible manner."

11:04 EST Blue Ridge Bankshares implements sabbatical leave program - The new sabbatical leave program begins at the five-year service mark. Blue Ridge Bank employees earn three weeks of sabbatical leave, which is in addition to the normal paid leave time allotment. Three weeks of sabbatical leave are added for each additional five years of service, peaking at twelve weeks of sabbatical leave with twenty years of service. Employees with over twenty years of service maintain twelve weeks of sabbatical leave at each five-year increment.

10:05 EST Encore Bank selects Q2 Holdings as strategic digital partner - Q2 Holdings announced that Encore Bank has selected Q2 as its strategic digital partner. Encore Bank will deploy the Q2 digital banking platform, along with several Q2 Catalyst commercial solutions. Leveraging the Q2 digital banking platform's extensive integration capabilities, Encore Bank will be able to grow its commercial lending, deposit and non-interest income business through a seamless digital experience that connects to its back-office processing systems.

10:03 EST Advanced Foot & Ankle Center uses Weave to increase reviews - Weave announced that Advanced Foot & Ankle Center has received over 1,900 Google reviews across their 13 offices since switching to Weave Unify while maintaining a 4.9/5 star rating. The increase in reviews has helped solidify Advanced Foot and Ankle Center as a leading and visible local provider, driving practice growth.

10:01 EST JetBlue opens Paisly travel booking platform to all travelers - JetBlue Travel Products, a subsidiary of JetBlue, announced it has opened access to its travel booking platform Paisly to all travelers, with a focus on TrueBlue members. The company said: "Paisly was previously available only to those booked on a JetBlue flight, but starting today, all travelers can use Paisly to book cars, stays and activities, all while earning TrueBlue points-even if they're taking different means of transportation to get to their destination. Giving all travelers the ability to book other travel components all in one place, with a 24/7 dedicated phone line to Paisly's helpful humans and one-point-of-contact for all their purchases, further positions JetBlue as a provider of high-quality travel options across the entire travel journey."

10:00 EST Benchmark Electronics falls -17.6% - Benchmark Electronics is down -17.6%, or -$5.03 to $23.63.

10:00 EST Hanesbrands falls -18.4% - Hanesbrands is down -18.4%, or -$1.60 to $7.11.

10:00 EST Silvergate Capital rises 19.2% - Silvergate Capital is up 19.2%, or $3.12 to $19.36.

09:59 EST PONOU Stock trading halted, volatility trading pause

09:47 EST Advanced Drainage falls -13.7% - Advanced Drainage is down -13.7%, or -$14.21 to $89.89.

09:47 EST e.l.f. Beauty rises 15.6% - e.l.f. Beauty is up 15.6%, or $9.12 to $67.63.

09:47 EST Carvana rises 29.2% - Carvana is up 29.2%, or $3.96 to $17.52.

09:42 EST Ford reports January U.S. sales up 2% to 146,356 vehicles - Ford Motor sales results were reported on the company's website. Reference Link

09:39 EST Genius Group LTD trading resumes

09:34 EST Genius Group LTD trading halted, volatility trading pause

09:28 EST Harley-Davidson 'remains optimistic on 2023 and beyond' - Says Japan now second largest market. Expects riding gear to become core competency of the brand. Says ended 2022 in "healthy inventory position." Says continues to see supply chain costs stabilize. Expects more modest inflation in 2023. Comments taken from Q4 earnings conference call.

09:21 EST Sabra provides update on disposition activity and North American transition - Sabra Health Care REIT (SBRA) announced that since September 30 the Company has received roughly $185M of gross proceeds related to previously disclosed disposition activity. In addition, the 24 properties formerly leased to North American have been successfully transitioned to Ensign (ENSG) and the Avamere Family of Companies . The disposition activity was almost entirely comprised of skilled nursing investments, including a sizable portfolio which sold for over $200,000 per bed and a cash yield in the mid-single digit range for the twelve-month period ending September 30. In aggregate, the cash yield on this disposition activity was approximately 7% for the twelve-month period ending September 30. The net proceeds from the disposition activity were used to repay borrowings under the Company's revolving credit facility. "We are pleased to announce the proceeds from this disposition activity as part of our previously communicated capital recycling strategy. We remain committed to thoughtfully allocating capital and prudently managing our balance sheet in this uncertain macro environment. We are also pleased to expand our relationship with Ensign and Avamere through the successful transition of the 24 properties formerly leased to North American," said Rick Matros, Sabra's CEO and Chair.

09:14 EST Fresh Del Monte and Moze Holding in Somalia-based, multi-year banana partnership - Fresh Del Monte Produce and Moze Holding Limited, a Talc Investment company, are pleased to announce the signing of a Somalia-based, multi-year banana partnership located in the heart of the previously famed banana belt area. This partnership will not only significantly reduce banana transport times, giving consumers in the Middle East and North Africa MENA access to fresher, lower-cost fruit, but will also aid in Somalia's economic resurgence. As part of the agreement, Fresh Del Monte will have operational oversight and train the team on the ground. In return, the global produce distributor will purchase its banana supply directly from Moze, the newly established banana farm. The fruit will be sold and marketed under the Fresh Del Monte brand for its markets in the Middle East, with the first harvest expected in 2024. "We are pleased to officially announce this partnership, which we believe is a game-changer for the banana industry in the region," said Mohammad Abu-Ghazaleh, Fresh Del Monte's Chairman and CEO. "The move to reestablish banana operations in Somalia makes sense on many accounts - from its strategic location on the Horn of Africa to fulfilling our mission of supplying our consumers with the freshest produce available - all while aiding in the country's recovery."

09:10 EST Definitive Healthcare introduces the Atlas Dataset - Definitive Healthcare introduced its Atlas Dataset, which provides the foundation for the company's healthcare commercial intelligence and powers Definitive Healthcare's existing products, analytics, and solutions. The Atlas Dataset ranked first or second in each of the top ten use cases for healthcare reference and affiliation data, according to an independent third-party research survey conducted in November 2022. "Over the last decade, we've been recognized as a leader in reference and affiliations data, helping clients gain unique intelligence on healthcare entities. We're excited to package up all the data that our clients know and love in the Atlas Dataset," said Robert Musslewhite, CEO of Definitive Healthcare. "With the Atlas Dataset, we're empowering customers to make strategic data-driven decisions based on up-to-date intelligence on the complex and broad healthcare ecosystem."

09:09 EST CleanSpark mined 697 bitcoin in January - CleanSpark released its unaudited bitcoin mining and operations update for the month ending January 31, 2023. January Bitcoin Mining Update: Bitcoin mined in January: 697, up 50% from December 2022; 2023 Calendar year bitcoin mined: 697; Total BTC holdings as of January 31: 301 BTC, up 32% from December 2022; Total BTC converted for operations and growth in January: 624; Currently deployed fleet of about 66,000 latest-generation bitcoin miners with a hashrate of 6.6 EH/s, up 7% from December 2022 and up 214% from January 2022. "We had a banner month, and not just because we mined a record number of bitcoin," said Zach Bradford, CEO. "We also had our most reliable month ever, achieving 98% uptime across all of our sites. This remarkable achievement is the direct result of some of the hardest working and most dedicated teams in the public bitcoin mining sector. This fact is one of the hallmarks of the CleanSpark way and it is foundational to our operational strategy as one of the largest proprietary miners in North America.

09:08 EST Artelo Biosciences completes enrollment of Phase 1b stage of CAReS trial - Artelo Biosciences announced that enrollment in the final cohort of the Phase 1b stage of its Cancer Appetite Recovery Study is now complete. The first stage of the CAReS clinical trial is intended to evaluate the safety of ART27.13. Following a review of initial treatment data from the Phase 1b, Artelo expects to select the optimal dose for the randomized Phase 2a stage of CAReS, which is designed to further explore safety and efficacy of ART27.13.

09:06 EST Canadian Pacific reports new record January for Canadian grain transport volume - Canadian Pacific moved 2.29 million metric tons of Canadian grain and grain products in January 2023, setting a new record for the month. CP has moved more than 15 MMT of Canadian grain and grain products thus far in the 2022-2023 crop year, exceeding the amount shipped by this time in the 2021-2022 crop year by more than 45%.

09:04 EST Amgen's Tezspire approved in U.S. for self-administration in severe asthma - Amgen (AMGN) and AstraZeneca (AZN) announced FDA approval of Tezspire for self-administration in a pre-filled, single-use pen for patients aged 12 years and older with severe asthma. First approved by the FDA in December 2021, Tezspire is the only biologic approved for severe asthma with no phenotype or biomarker limitation within its approved label. In 2020, Amgen and AstraZeneca updated the 2012 collaboration agreement for TEZSPIRE. Both companies will continue to share costs and profits equally after payment by AstraZeneca of a mid-single-digit royalty to Amgen. AstraZeneca continues to lead development and Amgen continues to lead manufacturing. Amgen and AstraZeneca will jointly commercialize Tezspire in North America. The majority - 92% - of healthcare providers, patients and caregivers were able to successfully administer Tezspire both in the clinic and at home throughout the PATH-HOME trial. Tezspire self-administration and the Tezspire pre-filled pen are also approved in the European Union and are under regulatory review in several other countries around the world.

09:03 EST Muscle Maker appoints Hannah Oh, Ray Shankar to board of directors - Muscle Maker announced the appointment of Ms. Hannah Oh and Mr. Ray Shankar to its Board of Directors effective March 1, 2023. Hannah Oh is currently the Head of Marketing Excellence with Bayer Crop Science for the Asia region. Ray Shankar is currently a Partner at Oon & Bazul LLP.

09:01 EST Honeywell expects Q1 to be most supply constrained of the year

08:53 EST Honeywell to continue to drive pricing actions to offset cost inflation

08:52 EST Silo Pharma issued U.S. patent covering SPC-15 in stress-induced disorders - Silo Pharma announced that the U.S. Patent and Trademark Office issued U.S. Patent 11,491,120, titled "Pharmacological Prophylactics Against Stress-Induced Affective Disorders In Females." The allowed claims protect the use of portfolio drug SPC-15 in a method of treating stress-induced affective disorders including anxiety and post-traumatic stress disorder. Through its commercial evaluation license agreement with Columbia University, the Company holds an option to license certain assets currently under development by Columbia, including potential treatments for stress-induced affective disorders and Alzheimer's disease.

08:48 EST Honeywell sees moderation in raw material inflation in 2023

08:47 EST Honeywell sees continuation of 'many' challenges faced in 2022 - Comments taken from Q4 earnings conference call.

08:46 EST Okta jumps 6% to $80.69 after announcing restructuring plan

08:44 EST BTCS announces key dates, information regarding Series V Distribution - BTCS is announcing key dates and releasing the following information for shareholders relating to the recently announced distribution of its newly created Series V Convertible Preferred stock. "I am pleased to announce that the special committee created by BTCS's board has set the Series V record and payment dates," said BTCS CEO Charles Allen. "We believe the Voucher represents an important step toward protecting our investors. With blockchain technology and instant settlement, intermediaries could be eliminated, thus reducing potential share imbalances and the risks and costs associated with traditional T+2 settlements. This move represents our commitment to innovation and delivering superior value to our investors."

08:43 EST Willis Towers Watson launches ESG Clarified platform - WTW introduced ESG Clarified, an analytics platform generating new insights to help organizations better understand and address their climate, sustainability and wider ESG risks and exposures. ESG Clarified offers a comprehensive, analytical solution, underpinned by multiple validated data sources to assist with trending insight, scenario analysis and reporting. Ben Fidlow, Global Head of Core Analytics at WTW, commented: "ESG Clarified joins several solutions our clients are already using to address ESG risks, including Climate Diagnostic, Risk Tolerance Clarified and D&O Quantified. We are excited to introduce ESG Clarified as an addition to our market-leading analytical solutions suite and we've made them all accessible through our Risk Intelligence Quantified (RiskIQ) platform."

08:41 EST MGO Global CEO announces key objectives for 2023 - Maximiliano Ojeda, Chairman and CEO of MGO Global, issued a letter to the Company's stockholders: "Successfully completing our Initial Public Offering and having our common stock now trading on The Nasdaq Capital Market is a direct reflection of effort of our collective team of professionals who never wavered in their confidence in MGO and worked in close collaboration to get the job done. This team included every member of MGO's staff, executive leadership and new Board of Directors, as well as our many trusted investment banking, legal and accounting partners, all of whom remained in firm lock-step as we progressed through the complex IPO process. There are simply no words adequate to express the depth of my gratitude to these people for their efforts on MGO's behalf. Moreover, I am humbled and incredibly thankful to the individual and institutional investors who have chosen to join us as fellow shareholders as we move forward in our journey as a publicly traded company. MGO co-founder and Chief Design Officer Ginny Hilfiger and I began this journey nearly five years ago with a mission to build a world class lifestyle brand portfolio company that empowers people to express their personal style and authenticity through high quality, thoughtfully designed and crafted apparel, accessories and homewares. Anchored by our flagship brand inspired by professional soccer phenom Leo Messi, MGO intends to use the capital raised in our IPO to help us achieve several key objectives in 2023, including: driving and amplifying the growth and expansion of The Messi Brand and The Messi Store, capitalizing on the experience and industry influence of our accomplished leadership team to identify and pursue strategic opportunities capable of accelerating our growth, and efficiently replicating and scaling our proven, end-to-end, global brand-building platform. Since the beginning of 2020, The Messi Store has welcomed more than 6.6 million visitors worldwide and processed orders for customers in 124 countries and territories, according to data supplied by our ecommerce platform provider, Shopify. Moreover, Leo's amazing performance on the pitch at the 2022 World Cup has led to the number of social media followers skyrocketing for Leo and for The Messi Store in recent months, resulting in combined social media reach that now exceeds 549 million fans globally. More specifically, Leo's social media following now stands at 425 million on Instagram, 113 million on Facebook, 1.4 million on YouTube and 8.04 million on Weibo; and The Messi Store has reached 1.7 million followers on Instagram and nearly 276,000 on Facebook. In the coming year, we look forward to tapping this enormous audience through creative programmatic advertising and social networking strategies designed to promote The Messi Brand and significantly boost consumer traffic and sales of our high quality line of Messi fashions...We have been very fortunate to recruit creative, committed and hard-working stars to our team. We hope to recruit many more in the future, and you can count on us rewarding and treating them well. Working together to execute MGO's short- and long-term growth strategies, we will measure our collective performance in terms of metrics most indicative of success in our industry: customer and revenue growth, the degree to which our customers continue to purchase from us on a repeat basis, and the strength of The Messi Brand and any other brands that we may add to our portfolio in the future."

08:39 EST Okta announces restructuring plan, to cut 300 employees - In a regulatory filing, on February 2, Okta announced to its employees a restructuring plan intended to reduce operating expenses and improve profitability. The plan involves a reduction of the company's workforce by approximately 300 full-time employees. In connection with the plan, the company estimates that it will recognize approximately $15M of restructuring charges in the fourth quarter of fiscal 2023 for future cash employee severance and benefits costs, which primarily will be paid in the first quarter of fiscal 2024. The company also expects to record an insignificant adjustment to its stock-based compensation expense in the first quarter of fiscal 2024 related to equity compensation for employees who were terminated. The company intends to exclude the charges associated with the plan from its non-GAAP financial measures.

08:38 EST Safe & Green CEO issues letter about shareholder reporting non-compliance - On February 2 Paul Galvin, Chairman and CEO of Safe & Green Holdings issued the following letter to stockholders. "This communication is to update you regarding the on-going situation pertaining to shareholder reporting non-compliance. We are aware of an investor who voted 693,600 shares at the Annual Shareholder Meeting without being in compliance with regulatory reporting requirements. The shareholder voted over 5% of the Company without filing any Section 13 Reports. ..Despite our best efforts, they have not filed to date and we believe continue to be active in the stock. Hence, adding additional non-compliance and violations of law each time. At this time, we have exhausted our efforts in this area. It is a regulatory matter and thus out of our hands."

08:35 EST PLBY Group announces results of rights offerings - PLBY Group announced the results of its previously announced $50 million rights offering which, together with the Company's previously announced registered direct offering, will provide the Company with gross proceeds of $65 million. Pursuant to the terms of the rights offering the Company is issuing, in the aggregate, 19,561,050 shares of the Company's common stock, par value $0.0001, at a subscription price of $2.5561 per share. The rights offering will provide the Company with gross proceeds of $50 million, before offering fees and expenses. The Company expects to use a minimum of 80% of the gross proceeds from the rights offering for repayment of senior debt under its credit agreement, and to use the remainder, if any, for other general corporate purposes. With such repayment of the debt, along with the $25 million repaid in December 2022, the Company will have repaid at least $65 million of the senior debt. Pursuant to the rights offering, holders subscribed assuming the subscription price was $3.50 per share. Since the Subscription Price was less than the Initial Price, excess subscription amounts paid by holders were applied to the purchase of additional shares of Common Stock. The excess amount for any remaining fractional shares of Common Stock will be returned to applicable stockholders as soon as practicable, in the form in which made. Such stockholders will not receive interest or a deduction on any payments refunded. Both the Company's largest beneficial owner of Common Stock, Rizvi Traverse Management, and the Company's Chief Executive Officer, Ben Kohn, fully exercised their basic subscription rights and exercised their over-subscription privileges in the rights offering. Pursuant to the authority of an independent committee of the Company's board of directors, in approving RTM's over-subscription the Committee required that RTM enter into a standstill agreement with the Company pursuant to which, among other limitations, RTM and its affiliates may not acquire more than 29.99% of the Company's outstanding Common Stock, resulting in the Company limiting RTM's total over-subscription in the rights offering such that it owns 29.99% of the Company's outstanding Common Stock as of the closing of the rights offering. Due to the rights offering being over-subscribed, the Company will not be issuing any shares of Common Stock pursuant to the backstop commitment made by purchasers in the previously announced registered direct offering, in which such purchasers agreed to purchase up to an additional $10 million of shares of Common Stock, only to the extent that the Company's rights offering was not fully subscribed. Accordingly, the total gross proceeds received by the Company, before applicable fees and expenses, from the registered direct offering were $15 million.

08:33 EST Etsy appoints Colin Stretch as Chief Legal Officer and Corporate Secretary - Etsy appointed Colin Stretch as Chief Legal Officer and Corporate Secretary, effective February 14. Colin comes to Etsy with 25 years of experience, including as former General Counsel of Facebook from 2013-2019. After Facebook, he spent two years as Leader-in-Residence at Columbia University Law School's Reuben Mark Initiative for Organizational Character & Leadership and, most recently, he was Of Counsel at Latham & Watkins. Earlier in his career, Colin clerked for Justice Stephen G. Breyer on the United States Supreme Court and Judge Laurence H. Silberman on the United States Court of Appeals for the D.C. Circuit. He will join Etsy's executive team.

08:27 EST Duos Technologies Group joins Webull Corporate Communications platform - Duos Technologies Group announced that the Company is one of approximately 35 Nasdaq-listed firms to be participating on the new Webull Corporate Communications Service Platform. The Duos Technologies portal on the Webull Platform will help provide the Company with a direct line of communication to shareholders and followers by providing instant notifications regarding corporate content such as company news, earnings reports, investor presentations, and more.

08:26 EST Harley-Davidson sees FY23 HDMC revenue growth 4%-7% - For the full year 2023, the company expects: HDMC: revenue growth of 4 to 7% and operating income margin of 14.1 to 14.6%. HDFS: operating income decline of 20 to 25%. LiveWire: motorcycle wholesale units 750-2,000 and operating income loss of $115M-$125M. Harley-Davidson capital investments of $225M-$250M.

08:25 EST Focus Financial announces acquisition proposal from Clayton, Dubilier & Rice - Focus Financial Partners announced that it had entered into an exclusivity agreement for a limited period with Clayton, Dubilier & Rice to engage in negotiations regarding the terms and definitive agreements whereby CD&R may potentially acquire Focus for $53 per share in cash. A Special Committee of the Board of Directors of Focus was formed on November 1, 2022 to evaluate a non-binding offer received from CD&R and to explore alternative transactions. After a series of negotiations with CD&R and outreach and meetings with other potential bidders, the Special Committee has approved the exclusivity agreement based on CD&R meeting the Special Committee's requirement of $53 per share. CD&R has communicated that its latest non-binding offer of $53 per share represented its "best and final" offer and that it was submitted with the understanding that there would be no further price negotiations. CD&R has also proposed that the transaction would be subject to a non-waivable approval of a majority of the voting power of disinterested shareholders. The contemplated purchase price of $53 per share represents a 36% premium to Focus' 60-day volume weighted average price as of yesterday's close and a 48% premium to Focus' closing stock price on December 28, 2022, the day the Special Committee specifically authorized its financial advisors to broaden their outreach and contact other potential bidders regarding interest in a definitive transaction. Funds managed by Stone Point Capital LLC are considering retaining a portion of their investment in Focus and providing new equity financing as part of the proposed transaction, subject to negotiation with CD&R of definitive agreements on mutually agreeable terms. Negotiations regarding definitive terms and agreements are ongoing and there is no certainty that final terms of any transaction will be agreed upon or, if agreed upon, completed. Any transaction would be subject to the completion of due diligence, Board and stockholder approval, regulatory approvals and other customary conditions. Focus will cease to be a publicly traded company if such a transaction is consummated. The Company and the Special Committee do not currently intend to comment further about this proposal unless and until a specific transaction is recommended by the Special Committee to, and approved by, the Board. The Special Committee has engaged Jefferies LLC and Goldman, Sachs & Co. LLC as its financial advisors.

08:23 EST DZS Saber-4400 optical transport technology chosen by Bonfire Fiber - DZS announced a partnership with open access innovation pioneer Bonfire Fiber that leverages the disruptive DZS Saber-4400 coherent optical metro and edge transport platform. Aligned with Bonfire's mission to eradicate digital inequality through a superior combination of business planning, engineering, construction and fiber operations, the new partnership with DZS enables Bonfire to leverage the environmentally hardened and extraordinarily scalable Saber-4400 to bring world-class broadband to underserved communities while delivering the lowest initial capital expense, CAPEX, for each project while enabling the lowest ongoing operational expense, OPEX. "Cost effective and scalable middle mile transport is essential to bringing long-term, sustainable success to communities that have historically been underserved and unserved by broadband," said Brian Hollister, CEO, Bonfire. "DZS understands this requirement, and the Saber-4400 platform supports our goal of having vendor-neutral scalability with an efficient, long-reach middle mile transport solution that can deliver up to 400Gbps per wavelength in a 1 Rack Unit hardened form factor."

08:21 EST A-Mark Precious Metals subsidiary announces agreement with CCG - A-Mark Precious Metals announced that its wholly-owned subsidiary, Collateral Finance Corporation, CFC, has entered into a branding and marketing agreement with Certified Collectibles Group, CCG, a leading third-party certification service focused on coins, paper currency, sports cards and other categories such as comic books and sports memorabilia. As part of the Agreement, CFC will be appointed as a non-exclusive "Approved Financing Service" of CCG and CCG will be appointed as a non-exclusive "Approved Grading Service" of CFC. CFC was founded in 2005 and has extended several hundred million dollars of loans to date with a history of no principal losses. This Agreement creates an opportunity for CFC to provide loans to CCG customers looking to access liquidity via their coins, paper currency or sports cards. Both companies plan to engage in co-marketing efforts to increase the respective brands' awareness and creation of the arrangement. "We are pleased to announce this new relationship with CCG as we extend CFC's lending services to their customer base and utilize their industry-leading authentication and collectibles rating services," said A-Mark CEO Greg Roberts. "We look forward to providing increased liquidity options to their customers through CFC's secured lending solutions."

08:18 EST Harsco Environmental reports double-digit improvement in safety performance - Harsco Corporation reported that its Harsco Environmental division recorded its third consecutive year of improvements in workplace health and safety. In 2022, Harsco Environmental achieved a Total Recordable Incident Rate of .45, exceeding its 2022 goal of .62 by 27 percent. Harsco Environmental's Visible Felt Leadership program, which launched in 2021, continued to drive improvements in the division's safety record. Visible Felt Leadership is an intentional leadership model focused on engaging and empowering employees to take personal responsibility for safety and communicate with their peers and leaders when they spot health and safety concerns. In 2022, Harsco Environmental added four International Organization for Standardization 45001 certified sites. With the addition of these four sites, Harsco Environmental has a total of 65 ISO 45001 certified sites globally. Harsco Environmental's ongoing pursuit of ISO 45001 certifications at its sites around the world demonstrates its commitment to upholding rigorous occupational health and safety standards.

08:17 EST MoonLake completes patient enrollment in Phase 2 trial of Nanobody sonelokimab - MoonLake Immunotherapeutics announced that it has completed enrollment of the target 210 patients randomized ahead of schedule in its global Phase 2 clinical trial evaluating sonelokimab in moderate-to-severe hidradenitis suppurativa, HS. The MIRA trial is the first global, randomized, double-blind, placebo-controlled trial using Hidradenitis Suppurativa Clinical Response, HiSCR, 75, a higher measure of clinical response, as its primary endpoint. It is evaluating different doses of sonelokimab, compared with placebo, with adalimumab as an active control reference arm, in patients with HS, a severely debilitating chronic skin condition, that results in irreversible tissue destruction. Kristian Reich, Founder and Chief Scientific Officer at MoonLake, commented: "The rapid completion of enrollment and randomization for our Phase 2 trial reflects the need for new treatment options and the clinical interest in evaluating the Nanobody(R) sonelokimab in hidradenitis suppurativa. In our view, and based on competitive data, sonelokimab's ability to efficiently inhibit IL-17F in addition to IL-17A could represent a major improvement in treating inflammation for this devastating disease. Sonelokimab's smaller size versus traditional antibodies and albumin-binding domain provide an opportunity for further efficacy. We thank patients and investigators for their participation in this important trial, and remain on schedule to announce top line results on the primary endpoint by mid-2023."

08:16 EST New paper highlights clinical utility of Natera's Renasight in kidney disease - Natera announced the publication of a new paper in Pediatric Nephrology, which highlights the clinical utility of Renasight in aiding the diagnosis and management of kidney disease. The publication can be found here. This paper reviews the case of a 16-year-old patient with sickle cell disease and kidney cysts. Natera's Renasight test, a genetic testing panel that analyzes 385 genes related to kidney disease, was administered to examine whether an additional genetic cause may have been contributing to the patient's kidney cysts. The test identified genetic variants which led to a diagnosis of autosomal dominant polycystic kidney disease , in addition to the patient's SCD. SCD and ADPKD are distinct genetic conditions that affect kidney function. SCD is routinely diagnosed in newborns whereas ADPKD is most often diagnosed in adulthood. While both conditions may include the presence of kidney cysts, the two conditions have different treatment regimens and complications. Furthermore, there is the potential that treatments effective in one condition may be harmful to the other.

08:15 EST Guardant Health, AnHeart Therapeutics team on NSLC companion diagnostics - Guardant Health announced a strategic collaboration on the development, regulatory approval and commercialization of the Guardant360 CDx and Guardant360 TissueNext assays as companion diagnostics for taletrectinib in the United States and European Union. Taletrectinib is an investigational ROS1 inhibitor for the treatment of adult patients with advanced or metastatic ROS1-positive non-small cell lung cancer NSCLC . AnHeart received U.S. Food and Drug Administration Breakthrough Therapy Designation BTD for taletrectinib on August 1 , for the treatment of adult patients with advanced or metastatic ROS1-positive NSCLC who are ROS1 tyrosine kinase inhibitor treatment naive or previously treated with crizotinib. BTD is intended to expedite the development and regulatory review of investigational treatments for serious or life-threatening conditions when preliminary clinical evidence indicates that the drug has the potential to substantially improve clinical outcomes compared with available therapies. The collaboration will focus on the use of the Guardant tests for comprehensive genomic profiling to identify patients with the specific tumor mutations that are targeted by taletrectinib.

08:13 EST Portillo's announces plans to open two additional locations in Texas - Portillo's announced plans to open two additional locations in the Lone Star State by the end of year. "Texas fans have come from near and far to enjoy Portillo's in The Colony. We're so thankful, and we've loved serving fans from across the beautiful state of Texas since opening in January," says Portillo's CEO Michael Osanloo. "We're thrilled to be expanding in the Dallas-Fort Worth area, bringing our unrivaled Chicago street food to even more fans and newcomers in the bustling cities of Allen and Arlington."

08:11 EST Elys Game Technology acquires Engage IT Services - Elys Game Technology announced that it has completed the acquisition of a premium software engineering and IT development firm, Engage IT Services. The firm offers best-in-class development of sportsbook and gaming applications for cloud, web, and mobile platforms, user experience development, customized business intelligence, digital transformation consulting, end-to-end project and product management, Microsoft solutions, and other engineering and development projects. The integration of the Engage team within our organization will greatly enhance our in-house engineering capabilities and addresses the abundance of incoming business, including the development of our US product offerings which includes retail opportunities and mobile solutions as well as the development of our global virtual gaming platform and global mobile solutions, while streamlining our current group engineering projects. On the same day the Company also obtained long-term commitments of 6 key IT, engineering, and risk and project management employees through the issuance of incentive shares vesting monthly over a period of 3 years. The deal is structured as an equity acquisition of 100% of the shares of Engage such that Engage will become a wholly owned subsidiary of Elys upon the terms and subject to the conditions set forth in the Share Purchase Agreement. The current Engage and Elys leadership and management team will remain in their current roles and their interest are aligned with that of our shareholders due to the equity nature of this transaction. Pursuant to the Agreement, Elys will issue approximately 3,018,462 shares of common stock, valued at EUR 1.08 million, which purchase price may be increased or decreased dependent upon the net financial position of Engage as determined by due diligence, on or prior to June 30, 2023. Subject to the repurchase option set forth in the Agreement, the Sellers will be restricted from disposing of the Shares for 36 months and the Company may repurchase the Shares issued for EUR 1.08 million in cash up to June 30, 2023.

08:09 EST Enphase Energy demonstrates bidirectional EV charger technology - Enphase Energy announced a demonstration of its bidirectional EV charger enabling vehicle-to-home and vehicle-to-grid functionality. This product will leverage the power of grid-forming IQ8 Microinverters and Ensemble energy management technology to seamlessly integrate into Enphase home energy systems. In addition, Enphase's bidirectional EV charger is expected to work with most EVs that support standards such as CCS and CHAdeMO.

08:07 EST Inovio's INO-4201 shows efficacy as Ebola booster in Phase 1b trial - Inovio announced positive results from a Phase 1b clinical trial evaluating INO-4201, a DNA vaccine candidate targeting Zaire Ebola virus, as a booster in healthy adult participants who previously received a single injection of Ervebo. In the trial, INO-4201 was well-tolerated and boosted humoral responses in 100% of 36 treated participants. INO-4201 was evaluated in a Phase 1b trial to assess its safety, tolerability, and immunogenicity in healthy adult participants who previously received a single injection of Ervebo, a vaccine approved by the FDA for the prevention of disease caused by Zaire ebolavirus in individuals 18 years of age and older. The trial was designed to test whether INO-4201 can be used as a booster in healthy participants previously vaccinated with Ervebo.

08:07 EST Orion's Voltrek to design, install EV charging infrastructure for pilot program - Orion Energy Systems announced its Voltrek subsidiary has secured a $1.5M contract for the design and installation of EV charging infrastructure to support an EV School Bus Pilot program for a large municipal school district. The pilot program - which includes EV charging infrastructure engineered to support the initial deployment of 20 electric school buses and future expansion of up to 145 electric school buses - utilizes the latest in DC fast-charging equipment and highlights Voltrek's capability to support large-scale fleet conversion to electrification. Orion CEO, Mike Jenkins, stated, "Voltrek is a pioneer in the EV charging industry with over a decade of success on projects throughout the nation. Their engineering, design, installation, service, and maintenance capabilities are a perfect fit for the electrification goals of this school bus pilot program. Supporting our customers' sustainability, efficiency and carbon reduction efforts over the long term is our core mission at Orion and Voltrek."

08:04 EST iRadimed board approves special cash dividend of $1.05 per share - The Board of Directors approved a special cash dividend of $1.05 per share. This special cash dividend is payable on February 21, 2023, to shareholders of record at the close of business on February 13, 2023.

08:01 EST Science 37 acquires Vault Health's life sciences platform - Science 37 Holdings announced that it has acquired the life sciences platform from Vault Health, a national leader in remote diagnostics and COVID testing, to further enhance clinical trial workflow orchestration and data interoperability capabilities of the Science 37 platform. The asset purchase accelerates Science 37's existing development plans for workflow features such as advanced scheduling and investigational product tracking, and data exchange with Electronic Data Capture and Electronic Medical Record systems. As a result, these capabilities will help reduce some of the manual efforts required to execute decentralized clinical trials and drive operational efficiencies. The added capabilities acquired with this transaction will enable Science 37 to avoid planned spending, and will be cash flow neutral for Science 37 within the calendar year, while adding additional capability today.

07:56 EST Hanesbrands drops 19% after Q4 guidance below consensus - Shares of Hanesbrands are dropping $19% or approximately $1.70 per share to $7.05 in early trading on Thursday after the company's quarterly and yearly guidance fall short of consensus expectations.

07:53 EST Arrowhead initiates Phase 1/2a study of ARO-MMP7 to treat PF - Arrowhead Pharmaceuticals announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-MMP7, the company's investigational RNA interference RNAi therapeutic designed to reduce the expression of matrix metalloproteinase 7 as a potential treatment for idiopathic pulmonary fibrosis . "MMP7 is thought to play multiple roles in IPF pathogenesis, including promoting inflammation and aberrant epithelial repair and fibrosis," said James Hamilton, M.D., MBA, chief of discovery and translational medicine at Arrowhead. "ARO-MMP7 offers a novel approach to potentially address the significant unmet medical need that exists for patients with IPF, who experience progressive decline of lung function, despite currently available therapies."

07:46 EST Nextech AR Solutions to pursue direct spinout of Toggle3D platform - Nextech AR Solutions (NEXCF) has determined to pursue a direct spinout of its generative AI powered Toggle3D platform through a wholly-owned subsidiary of the Company. The transaction is currently anticipated to proceed by way of plan of arrangement pursuant to which the Toggle3D platform and associated assets will be spun out into a new Subco, but will be subject to final tax and legal structuring considerations. Evan Gappelberg, CEO of Nextech AR commented, "The spin-out of ARway Corporation (ARWYF) on October 26th, 2022 has proven to be a tremendously successful method to unlock value for Nextech shareholders. As of February 1, 2023, ARway is trading at $1.25 with 26.5 million shares issued, which is worth $33.1 million. Nextech still retains ownership of 13 million shares which are worth $16 million dollars from essentially zero prior to the spin out. Now we are announcing that we are going to do the same thing with Toggle3D. We believe there is a tremendous amount of shareholder value currently trapped inside Nextech and these spin-outs are aimed at unlocking that value by listing pure-play technology companies. We believe that Toggle3D is now commercially ready to disrupt the $11billion CAD market and once it's spun out, we believe that just like ARway, it will create value for Nextech shareholders. This Toggle3D spin-out and the possibility of additional future spin-outs are intended to unlock the value of the technology that we have been heavily investing in, incubating and building inside Nextech for the last 4 years." The Arrangement, if completed, is anticipated to result in, among other things, Nextech retaining approximately 65% of the issued and outstanding shares of Subco upon completion of the transaction, approximately 20% of the Subco Shares being distributed directly to Nextech shareholders on a pro rata basis; and approximately 15% of the Subco Shares being distributed to certain service providers of Nextech in consideration of past services, as calculated prior to completion of the Private Placement following which the above percentages will be adjusted on a pro rata basis. In connection with the Arrangement, Nextech intends to seek a direct listing of the Subco Shares on the Canadian Securities Exchange.

07:45 EST IntercontinentalExchange boosts dividend 11% to 42c per share - Intercontinental Exchange announced board authorization of its first quarter 2023 dividend of 42c per share, up 11% from its previous $ 38c per share quarterly dividend in 2022. The first quarter cash dividend is payable on March 31 to stockholders of record as of March 17 . The ex-dividend date is March 16, 2023.

07:43 EST Saputo announces additional capital investments, optimization initiatives - Saputo announces additional capital investments and consolidation initiatives intended to further streamline and enhance its manufacturing footprint in its USA Sector. This announcement is part of the continued execution of the Company's Global Strategic Plan. Highlights include: Construction of a new, cut-and-wrap facility in Franklin, Wisconsin, creating 600 jobs; Expansion of string cheese operations on the West Coast of the USA; Permanent closure of its Big Stone, South Dakota, Green Bay, Wisconsin, and South Gate, California, facilities. Construction is underway on a greenfield facility in Franklin, Wisconsin, to consolidate and modernize the Company's cut-and-wrap activities. This state-of-the-art facility will become the centre of Saputo's expanded cut-and-wrap capabilities in the Midwest of the USA and is expected to result in the creation of 600 jobs. This new facility represents an investment of C$240 million and is slated to be operating at full capacity by the third quarter of fiscal 2025. Once operational, Saputo anticipates transferring existing packaging operations from other manufacturing sites to its new facility in Franklin. Consequently, the Company intends to permanently close its Big Stone, South Dakota, and Green Bay, Wisconsin, facilities in the third quarter of fiscal 2024, and the third quarter of fiscal 2025, respectively. After ceasing cut-and-wrap activities at its Bardsley Street, Tulare, California, facility, as announced in fiscal 2022, the Company now intends to invest C$75 million to convert this location into a string cheese packaging facility. The investment will help support the Company's growth ambitions and sustain its leadership position in the string cheese product category. The facility is slated to be operating at full capacity by the third quarter of fiscal 2025. As a result of this optimization initiative, Saputo intends to permanently close its South Gate, California, facility in the fourth quarter of fiscal 2025, and transfer existing operations from this facility to its newly converted Bardsley Street facility. These capital investments and consolidation initiatives in the Company's USA Sector are expected to yield financial benefits beginning in the fourth quarter of fiscal 2024 and contribute to their full potential of approximately C$74 million annually by the end of fiscal 2027. Costs related to the capital investments and consolidation initiatives outlined above will be approximately C$23 million after taxes, which include a non-cash fixed assets write-down of approximately C$13 million after taxes. These costs will start to be recorded in the fourth quarter of fiscal 2023. Approximately 720 employees will be impacted by the above-mentioned consolidation initiatives. Impacted employees will be offered the opportunity to relocate to other Saputo facilities and, if no positions are available, they will be provided with severance and outplacement support.

07:41 EST SunCoke Energy sees 2023 adjusted EBITDA $250M-$265M - Domestic coke total production is expected to be approximately 4.0 million tons. Consolidated Net Income is expected to be between $59M-$76M. Capital expenditures are projected to be approximately $95M. Operating cash flow is estimated to be between $200M-$215M. Cash taxes are projected to be $12M-$16M.

07:38 EST Marathon Gold provides assay results on final 26 in-fill drill holes in 2022 - Marathon Gold Corporation provides assay results on the final twenty-six in-fill drill holes completed during 2022 at the Berry Deposit, part of the Valentine Gold Project located in central Newfoundland. Matt Manson, President and CEO, commented: "With this final batch of 2022 Berry drill results, we continue to see intercepts of high-grade mineralization outside of Berry's currently modeled mineralized domains. As a reminder, this in-fill program was designed to target areas of the deposit assessed to comprise primarily un-mineralized waste rock. As with our previous batch of results, we are delineating a sizeable domain of quartz-tourmaline-pyrite veining at the base of the mineral resource pit shell. In this case, it is at the northeastern limit of the deposit and represents the deeper extension of one of three northeast plunging ore shoots. This area was targeted with an extension of the 2020 diamond drill hole VL-20-882, and is illustrated in long-section in Figure 4 and cross-section in Figures 5 and 6. The 2022 in-fill drilling at Berry has been very successful in delivering new areas of mineralization, and supports our assessment that additional mineable ounces remain to be delineated within the scope of the Project's current mine plan."

07:37 EST Red Cat announces Utah Governor recently toured HQ of subsidiary Teal Drones - Red Cat reports that Utah Gov. Spencer Cox recently toured the Salt Lake City HQ of Red Cat subsidiary Teal Drones. The visit, which took place on Jan. 25, was designed to help educate the governor on Teal's operations, the company's impact on the national aerospace and defense industries, and the opportunities and challenges facing the local industries in Utah. "We discussed ways in which the state can support our efforts across regulation and deployments," said Teal Founder and CEO George Matus. "The sky is literally the limit for Teal, and we're grateful for the governor's interest in aiding the growth of our company and Utah's broader aerospace and defense sector."

07:35 EST PharmaTher announces FDA granted orphan drug designation to KETARX - PharmaTher announced that the U.S. Food and Drug Administration has granted orphan drug designation to KETARX for the treatment of Rett Syndrome, a rare genetic neurological disorder. Ketamine has been subject to a Phase 2 clinical trial for Rett syndrome. Unpublished results from this study will be evaluated to support a potential Phase 3 clinical study and obtain FDA agreement on a regulatory plan for approval via the 505(b)(2) regulatory pathway. PharmaTher currently holds five orphan drug designations granted by the FDA for KETARX, which include: Treatment of Rett Syndrome; Prevention of Ischemia-reperfusion injury from organ transplantation; Treatment of Status Epilepticus; Treatment of Amyotrophic Lateral Sclerosis; and Treatment of Complex Regional Pain Syndrome. "We are committed to unlocking the potential of KETARX for rare disorders, and the addition of the Rett syndrome program to our four FDA-approved orphan drug designations strengthens our position in leading the advancement of ketamine for unmet medical needs in mental health, neurological and pain disorders," said Fabio Chianelli, CEO of PharmaTher.

07:33 EST CME Group reports January ADV 21.7M contracts

07:32 EST Tradeweb Markets reports January 2023 total trading volume of $23.2TN - Tradeweb Markets reported total trading volume for January 2023 of $23.2TN . Average daily volume ADV for the month was $1.15tn, an increase of 2.8 percent (%) year-over-year YoY Tradeweb's broad offering across products, geographies and client sectors resulted in a number of records for J We continued to help our clients navigate a complex macroeconomic backdrop, including evolving central bank policy, sustained elevated volatility, economic concerns and a strong U.S. dollar (USD

07:27 EST Polestar, Luminar to deepen their partnership - Polestar (PSNY) and Luminar (LAZR) announced plans to deepen their partnership by expanding the integration of Luminar's technology on the Polestar 5 - the electric 4-door GT expected to launch in 2024 based on the Polestar Precept concept car. This expanded partnership provides a foundation to further collaborate on lidar integration and design on Polestar's future vehicles. Both the Polestar 3 and Polestar 5 will integrate Luminar's long-range Iris lidar and software into the roofline. Coinciding with the announcement, sales of Polestar 3 with lidar have been brought forward so that customers in initial markets can now place orders for Polestar 3 with lidar, with deliveries expected in 2024.

07:25 EST NRx Pharmaceuticals reports recommendations of DSMB for NRX-101 trial - NRx Pharmaceuticals reported the recommendations of an independent Data Safety Monitoring Board, or DSMB, which reviewed the safety findings of the first fifty enrolled participants in the company's phase 2 clinical trial of NRX-101 for the treatment of Severe Bipolar Depression and Subacute Suicidal Ideation or Behavior. NRX-101 is a proprietary fixed dose combination of D-cycloserine and lurasidone. It is the only antidepressant currently in clinicals trials for patients with Bipolar Depression with acute or sub-acute suicidality, which also entails an NMDA component, similar to Auvelity and Spravator. Unlike the company's previously completed Phase 2 study which enrolled acutely suicidal patients, this current Phase 2 study addresses the needs of the much larger population of patients with bipolar depression and sub-acute levels of suicidality, i.e., not requiring stabilization in a clinical setting, who are cared for in the outpatient setting, including doctors' offices, community mental health centers, and outpatient clinics. The company's Bipolar Depression with Acute Suicidal Ideation or Behavior, or ASIB, study requires that patients first be stabilized in a clinical setting, patients enrolled in this current Phase 2 trial are randomly assigned to NRX-101 or lurasidone - a widely used drug indicated for the treatment of bipolar depression. The DSMB recommended that enrollment in the trial continue as planned and identified no drug-related Serious Adverse Events or other safety issues of concern. The company anticipates that the DSMB will examine unblinded study data in March to assess the study for safety, potential futility, and conditional power. The company views today's safety finding as important because this is the first time, to the company's knowledge that patients with bipolar depression and subacute suicidal ideation and behavior have been actively recruited into an outpatient clinical trial of a novel NMDA based antidepressant.

07:24 EST Mindset Pharma receives allowance for Family 1 U.S. patent application - Mindset Pharma announced that the United States Patent and Trademark Office has granted allowance for another of Mindset's Family 1 patent applications, number 17/743,718, titled "Psilocin Derivatives As Serotonergic Psychedelic Agents for the Treatment of CNS Disorders." Included in this patent are certain deuterated psilocybin analogs from Family 1. Family 1 consists of psilocybin-inspired drug candidates that demonstrate improved pharmacokinetic, efficacy and safety profiles, with reduced potential side effects and evidence of increased target engagement, in pre-clinical studies. This application is one of a family of applications having a priority date of February 4, 2020.

07:21 EST CME Group raises quarterly dividend 10% to $1.10 from $1.00 per share - The dividend is payable March 27 to shareholders of record as of March 10.

07:20 EST CME Group raises quarterly dividend 10% to $1.10 from $1.00 per share

07:18 EST Verisk Analytics announces closing of Wood Mackenzie sale - Verisk announced the closing of the sale of Wood Mackenzie to an affiliate of Veritas Capital, a leading investor at the intersection of technology and government. "This marks a significant value-creating step for Verisk, which returns the company to its roots as a dedicated strategic partner to the global insurance industry," said Lee Shavel, president and CEO, Verisk. "We'll continue to execute our strategy to deliver long-term sustainable growth by enabling our customers to make better decisions, increase efficiency and reduce operating expenses, while delivering a better experience to their customers."

07:16 EST SweetWater Brewing Company adds crisp lager to year-round lineup - SweetWater Brewing Company, a subsidiary of Tilray Brands, launches a new crisp lager to its year-round craft beer lineup. The new SweetWater Lager, a clean-bodied beer elevated with spicy floral hop notes, is now available on draft and will be available in 12-packs of 12-ounce cans in select retailers across the U.S. beginning March 2023.

07:16 EST Emerita Resources announces results from 12 additional drill holes - Emerita Resources announces assay results from 12 additional drill holes from the 2022 - 2023 delineation drilling program at La Romanera Deposit at its wholly owned Iberian Belt West project. IBW hosts three previously identified massive sulphide deposits: La Infanta, La Romanera and El Cura. All deposits are open for expansion along strike and at depth. Joaquin Merino, P.Geo., President of Emerita, notes, "Our drill campaign remains on track, and we plan to lock the database in mid-February in order to proceed with the initial NI 43-101 mineral resource estimate for the IBW Project. We expect to have the mineral resource estimate completed in early Q2. We are presently reviewing proposals for metallurgical testing and this work will commence this quarter also. Our environmental baseline studies are also progressing and expected to be completed in April. The baseline study is a key deliverable for the permitting process."

07:15 EST First Wave BioPharma announces first patient screened for Phase 2 SPAN trial - First Wave BioPharma announced that the first patient was screened for the Phase 2 SPAN clinical trial investigating an enhanced enteric microgranule delivery formulation of adrulipase for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis. Patient dosing is expected to commence by mid-February with topline results from the study to be available by mid-2023. "We are very pleased that patient screening has begun so soon after initiating the Phase 2 clinical trial," said James Sapirstein, President and CEO of First Wave BioPharma. "This urgency speaks to the collective focus of First Wave's clinical development team, the investigators and trial sites, and our CRO partner to conduct a successful Phase 2 clinical trial. Ultimately, our goal is to provide CF and chronic pancreatitis patients with a recombinant, non-porcine-derived therapeutic option that better addresses the numerous, life-altering symptoms they experience on a daily basis as a result of EPI." The Phase 2 multi-center clinical trial is designed to investigate the safety, tolerability and efficacy of an enteric microgranule delivery formulation for adrulipase in a titrated dose-escalation study involving an estimated twelve patients. The primary efficacy endpoint is the coefficient of fat absorption, with secondary endpoints of stool weight, signs and symptoms of malabsorption and coefficient of nitrogen absorption. Three clinical trial sites in the U.S. will be participating in the trial.

07:13 EST Tonix Pharmaceuticals announces acquisition of Healion Bio - Tonix Pharmaceuticals announced an agreement whereby Tonix has acquired all of the assets of Healion Bio, including its entire portfolio of next-generation antiviral technology assets. Healion's drug portfolio includes a class of broad-spectrum small molecule oral antiviral drug candidates with a novel host-directed mechanism of action. Host-directed antivirals modulate human cells and tissues and are different from direct-acting antivirals which inhibit virus proteins and processes. Tonix's TNX-3900, formerly known as HB-121, are cathepsin protease inhibitors, some of which have strong activity in vitro against SARS-CoV-2. "We are excited to develop Healion's drug programs that include TNX-3900, which is a class of drugs with potential broad spectrum anti-viral activity, either as monotherapies or in combination with other antivirals", said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. "Broad-spectrum antiviral agents have the potential to reduce viral load and allow the adaptive immune system to alert the other arms of the immune system to mount a protective response. Examples of other classes of host-directed antivirals that have been approved by the U.S. Food and Drug Administration include alpha interferon like Pegasys for viral hepatitis, the CCR5 antagonist Selzentry for HIV, and the anti-IL-6 receptor antagonist monoclonal antibody Actemra for COVID-19."

07:10 EST Gilat Satellite awarded multimillion-dollar contract for SATCOM expansion - Gilat Satellite Networks announced that the company was awarded a multimillion-dollar contract for the expansion of satellite communications, SATCOM, capabilities on trains in Asia-Pacific. Gilat's ER7000 SATCOM On-The-Move antennas were chosen by a leading integrator, for installation on trains to provide continuous internet access to passengers travelling across the Asia-Pacific region. "For many applications, SATCOM on-the-move is the only choice for reliable, continuous, and quickly deployable broadband connectivity. This project is an excellent example of how Gilat antenna systems can be used to provide better management of complex transportation networks, as well as reliable internet coverage for passengers," said Amir Yafe, VP of Mobility & Global Accounts at Gilat. "We are excited with the prospect of working on more projects like these to be deployed in the future."

07:09 EST Clearside Biomedical announces 6-month results from OASIS extension study - Clearside Biomedical announced positive results from the Extension Study of its OASIS Phase 1/2a clinical trial of CLS-AX administered by suprachoroidal injection via Clearside's SCS Microinjector(R) in neovascular age-related macular degeneration participants. These results include the final six-month data from all participants in the Extension Study and augment the previously reported 3-month results and interim extension data. George Lasezkay, Pharm.D., J.D., Clearside's President and Chief Executive Officer, commented, "We made tremendous progress in 2022 with the commercialization of our first suprachoroidal product by Bausch + Lomb and the positive safety and durability results from our Phase 1/2a OASIS trial. As we advance our CLS-AX wet AMD program with the initiation of our ODYSSEY Phase 2b trial, we continue to build on this significant momentum and will further increase awareness of the broad potential in delivering therapies to the back of the eye using our proprietary SCS platform technology."

07:08 EST Vista Outdoor names Gary McArthur as interim CEO, succeeding Chris Metz - Vista Outdoor announced that Gary McArthur, a member of the company's Board of Directors, has been appointed Interim CEO, effective immediately. McArthur succeeds Chris Metz, who agreed to resign as CEO and director at the request of the Vista Outdoor Board based on the Board's loss of confidence in his leadership for reasons not involving financial reporting or internal controls.

06:43 EST Advanced Drainage raises quarterly dividend 9% to 12c per share - To be paid on March 15 to shareholders of record at the close of business on March 1.

06:39 EST Merck reports Q4 Keytruda sales $5.45B vs. $4.58B a year ago

06:36 EST Essent Group to acquire Title insurance operations from Finance of America - Essent Group (ESNT) has entered into an agreement through its subsidiary Essent US Holdings to acquire Agents National Title and Boston National Holdings from Incenter, a subsidiary of Finance of America (FOA) for $100M. Agents National Title, based in Missouri, is a title insurance underwriter with 44 state licenses, and issues title insurance products through a network of title insurance agents. Boston National Title is an independent title agency based in North Carolina that provides title and settlement services, with licenses in 40 states and the District of Columbia. The closing of this transaction is subject to regulatory approvals.

06:32 EST Merck sees FY23 adjusted gross margin about 77%

06:10 EST Digihost regains compliance with Nasdaq minimum bid price requirement - Digihost has received formal notice from Nasdaq stating that the company has regained compliance with the minimum bid price requirement for continued listing on Nasdaq. The notice the company received from Nasdaq on February 1, 2023 noted that the company evidenced a closing bid price of its common subordinate voting shares on Nasdaq at or greater than the $1.00 per share minimum requirement for the last 10 consecutive business days.

06:04 EST Guardant Health 'pleased' with ruling in Illumina case - Guardant Health (GH) issued the following statement regarding the favorable recommendation by U.S. District Court Magistrate Judge Christopher Burke that nearly all claims brought by Illumina (ILMN) against Guardant Health in a lawsuit filed on March 17, 2022, be dismissed: "We are pleased with Judge Burke's recommendation that nearly all of Illumina's claims be dismissed as filed. We continue to believe that Illumina has no basis for challenging the ownership of our patents and that this lawsuit is nothing more than an attempt to impede our mission to improve cancer care and save patients' lives."

06:03 EST FirstCash says outlook for 2023 'highly positive' - "The company's outlook for 2023 is highly positive, with expected year-over-year growth in revenue and earnings in all segments driven by the continued growth in earning asset balances coupled with recent store additions as we begin the year."

05:53 EST BIT Mining regains compliance with NYSE - BIT Mining announced that it has received a letter from the New York Stock Exchange, notifying the company that it has regained compliance with the NYSE's continued listing standards.

05:19 EST Shell announces $4B share buyback program - Shell announced the commencement of a $4B share buyback program covering an aggregate contract term of approximately three months. The purpose of the program is to reduce the issued share capital of the company. All shares repurchased as part of the program will be cancelled. It is intended that, subject to market conditions, the program will be completed prior to the company's Q1 results announcement, scheduled for May 4. The company has entered into an arrangement with a single broker consisting of three irrevocable, non-discretionary contracts, to enable the purchase of ordinary shares on both London market exchanges and Netherlands exchanges for a period up to and including April 28. The aggregate maximum consideration for the purchase of ordinary shares under the London contracts is $2.25B and the maximum consideration for the purchase of ordinary shares under the Netherlands contract is $1.75B. Purchases under the London contracts will be carried out in accordance with the company's authority to repurchase shares on-market and will be effected within certain contractually agreed parameters. Purchases under the Netherlands contract will be carried out in accordance with the company's authority to repurchase shares off-market pursuant to the off-market share buyback contract approved by its shareholders and the parameters set out therein. The maximum number of ordinary shares which may be purchased or committed to be purchased by the company under the program is 387,374,130, which is the maximum number remaining as of the date of this announcement pursuant to the relevant authorities granted by shareholders at the company's 2022 Annual General Meeting.

05:06 EST Aramark to sell 50% equity stake in AIM Services to Mitsui & Co, for $535M - Aramark announced an agreement to sell its 50% equity stake in AIM Services to Mitsui & Co., Ltd. for $535M. The company will use the proceeds from the transaction toward debt repayment. AIM Services was established as a joint venture between Aramark and Mitsui Group companies in 1976 to provide food services to clients across a variety of business sectors in Japan. The transaction is anticipated to close at the beginning of Aramark's fiscal third quarter, subject to customary closing conditions and approvals.